Chemically modified tetracycline-3 (CMT-3): A novel inhibitor of the serine proteinase, elastase

Pharmacological Research

Volumn 64, Issue 6, 2011, Pages 595-601

  Gu, Ying ^a   Lee, Hsi Ming ^a   Simon, Sanford R ^a   Golub, Lorne M ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Chemically modified tetracycline; Matrix metalloproteinase; Neutrophil elastase; Serine proteinase

Indexed keywords

ALPHA 1 ANTITRYPSIN; COLLAGENASE 3; CYTOKINE; DOXYCYCLINE; GELATINASE A; GELATINASE B; INCYCLINIDE; INTERSTITIAL COLLAGENASE; LEUKOCYTE ELASTASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 20; NEUTROPHIL COLLAGENASE; SERINE PROTEINASE INHIBITOR; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CONNECTIVE TISSUE; CYTOKINE PRODUCTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PERIODONTAL DISEASE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; HUMANS; MATRIX METALLOPROTEINASES; PANCREATIC ELASTASE; SERINE PROTEINASE INHIBITORS; TETRACYCLINES;

EID: 80054096571     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.05.011     Document Type: Article

References (47)

1. L.M. Golub, H.M. Lee, M.E. Ryan, W.V. Giannobile, J. Payne, and T. Sorsa Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms Adv Dent Res 2 2 1998 12 26
2. A.M. Manicone, and J.K. McGuire Matrix metalloproteinases as modulators of inflammation Semin Cell Dev Biol 19 1 2008 34 41 (Pubitemid 350235986)
3. C.T. Pham Neutrophil serine proteases: specific regulators of inflammation Nat Rev Immunol 6 7 2006 541 550 (Pubitemid 43980526)
4. U. Gullberg, E. Andersson, D. Garwicz, A. Lindmark, and I. Olsson Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development Eur J Haematol 58 3 1997 137 153 (Pubitemid 27183463)
5. M. Faurschou, and N. Borregaard Neutrophil granules and secretory vesicles in inflammation Microbes Infect 5 14 2003 1317 1327 (Pubitemid 37410245)
6. C. Salaün, D.J. James, J. Greaves, and L.H. Chamberlain Plasma membrane targeting of exocytic SNARE proteins Biochim Biophys Acta 1693 2 2004 81 89 (Pubitemid 39094011)
7. Y. Weinrauch, D. Drujan, S.D. Shapiro, J. Weiss, and A. Zychlinsky Neutrophil elastase targets virulence factors of enterobacteria Nature 417 6884 2002 91 94 (Pubitemid 34498822)
8. O. Wiedow, and U. Meyer-Hoffert Neutrophil serine proteases: potential key regulators of cell signalling during inflammation J Intern Med 257 4 2005 319 328 (Pubitemid 40461184)
9. C.A. Owen, M.A. Campbell, P.L. Sannes, S.S. Boukedes, and E.J. Campbell Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases J Cell Biol 131 3 1995 775 789
10. S.E. Williams, T.I. Brown, A. Roghanian, and J.M. Sallenave SLPI and elafin: one glove, many fingers Clin Sci (Lond) 110 1 2006 21 35 (Pubitemid 43059043)
11. T. Moreau, K. Baranger, S. Dadé, S. Dallet-Choisy, N. Guyot, and M.L. Zani Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family Biochimie 90 2 2008 284 295 (Pubitemid 351172573)
12. C. Vogelmeier, R.C. Hubbard, G.A. Fells, H.P. Schnebli, R.C. Thompson, and H. Fritz Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor Clin Invest 87 2 1991 482 488
13. C.C. Taggart, G.J. Lowe, C.M. Greene, A.T. Mulgrew, S.J. O'Neill, and R.L. Levine Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor J Biol Chem 276 36 2001 33345 33352
14. O. Wiedow, J.M. Schröder, H. Gregory, J.A. Young, and E. Christophers Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence J Biol Chem 265 25 1990 14791 14795
15. J.M. Sallenave, and A.P. Ryle Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor Biol Chem Hoppe Seyler 372 1 1991 13 21
16. G.M. Tremblay, J.M. Sallenave, E. Israél-Assayag, Y. Cormier, and J. Gauldie Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung Am J Respir Crit Care Med 154 4 Pt 1 1996 1092 1098
17. A.B. Lentsch, J.A. Jordan, B.J. Czermak, K.M. Diehl, E.M. Younkin, and V. Sarma Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation Am J Pathol 154 1 1999 239 247 (Pubitemid 29031631)
18. P.P. Clausen Alpha-1-antitrypsin globules in liver biopsies Acta Pathol Microbiol Scand A 88 4 1980 225 230 (Pubitemid 10086110)
19. D.H. Perlmutter, R.M. Kay, F.S. Cole, T.H. Rossing, D. Van Thiel, and H.R. Colten The cellular defect in alpha 1-proteinase inhibitor (alpha 1-PI) deficiency is expressed in human monocytes and in Xenopus oocytes injected with human liver mRNA Proc Natl Acad Sci USA 82 20 1985 6918 6921 (Pubitemid 16209665)
20. J.F. Mornex, A. Chytil-Weir, Y. Martinet, M. Courtney, J.P. LeCocq, and R.G. Crystal Expression of the alpha-1-antitrypsin gene in mononuclear phagocytes of normal and alpha-1-antitrypsin-deficient individuals J Clin Invest 77 6 1986 1952 1961 (Pubitemid 16062652)
21. E. Perlino, R. Cortese, and G. Ciliberto The human alpha 1-antitrypsin gene is transcribed from two different promoters in macrophages and hepatocytes EMBO J 6 9 1987 2767 2771
22. I. Kushner, and A. Mackiewicz Acute phase proteins as disease markers Dis Markers 5 1 1987 1 11 (Pubitemid 17063156)
23. A. Janoff Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis Am Rev Respir Dis 132 2 1985 417 433 (Pubitemid 15229406)
24. P. Humbert, B. Faivre, R. Gibey, and P. Agache Use of anti-collagenase properties of doxycycline in treatment of alpha 1-antitrypsin deficiency panniculitis Acta Derm Venereol 71 3 1991 189 194
25. H. Ohbayashi Neutrophil elastase inhibitors as treatment for COPD Expert Opin Investig Drugs 11 7 2002 965 980 (Pubitemid 34732715)
26. X. Wang, K.F. Li, E. Adams, and A. Van Schepdael Matrix metalloproteinase inhibitors: a review on bioanalytical methods. Pharmacokinetics and metabolism Curr Drug Metab 12 2011 395 410
27. P. Van Lint, and C. Libert Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation J Leukoc Biol 82 6 2007 1375 1381 (Pubitemid 350276947)
28. N.T. Le, M. Xue, L.A. Castelnoble, and C.J. Jackson The dual personalities of matrix metalloproteinases in inflammation Front Biosci 12 2007 1475 1487 (Pubitemid 46846846)
29. L.M. Golub, N.S. Ramamurthy, T.F. McNamara, R.A. Greenwald, and B.R. Rifkin Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs Crit Rev Oral Biol Med 2 3 1991 297 321
30. H. Birkedal-Hansen, W.G.I. Moore, M.K. Bodden, L.J. Windsor, B. Birkedal-Hansen, and A. DeCarlo Matrix metalloproteinase: a review Crit Rev Oral Biol Med 4 2 1993 197 250
31. T. Nakamura, I. Ebihara, N. Shimada, H. Shoji, and H. Koide Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment Am J Med Sci 316 6 1998 355 360 (Pubitemid 29019588)
32. K.A. Yassen, H.F. Galley, and N.R. Webster Matrix metalloproteinase-9 concentrations in critically ill patients Anaesthesia 56 8 2001 729 732 (Pubitemid 32755137)
33. L.M. Golub, H.M. Lee, G. Lehrer, A. Nemiroff, T.F. McNamara, and R. Kaplan Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action J Periodontal Res 18 5 1983 516 526 (Pubitemid 14221747)
34. L.M. Golub, K. Suomalainen, and T. Sorsa Host modulation with tetracyclines and their chemically modified analogues Curr Opin Dent 2 1992 80 90
35. Y. Gu, H.M. Lee, E.J. Roemer, L. Musacchia, L.M. Golub, and S.R. Simon Inhibition of tumor cell invasiveness by chemically modified tetracyclines Curr Med Chem 8 3 2001 261 270 (Pubitemid 32409778)
36. Y. Gu, H.M. Lee, L.M. Golub, T. Sorsa, Y.T. Konttinen, and S.R. Simon Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines Ann Med 37 6 2005 450 460 (Pubitemid 41476130)
37. B.L. Lokeshwar, M.G. Selzer, B.Q. Zhu, N.L. Block, and L.M. Golub Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model Int J Cancer 98 2 2002 297 309 (Pubitemid 34150817)
38. M. Cianfrocca, T.P. Cooley, J.Y. Lee, M.A. Rudek, D.T. Scadden, and L. Ratner Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study J Clin Oncol 20 1 2002 153 159 (Pubitemid 34032606)
39. M.A. Rudek, W.D. Figg, V. Dyer, W. Dahut, M.L. Turner, and S.M. Steinberg Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer J Clin Oncol 19 2 2001 584 592 (Pubitemid 32112874)
40. B.J. Dezube, S.E. Krown, J.Y. Lee, K.S. Bauer, and D.M. Aboulafia Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study J Clin Oncol 24 9 2006 1389 1394 (Pubitemid 46622003)
41. L.M. Golub, M. Wolff, S. Roberts, H.M. Lee, M. Leung, and G.S. Payonk Treating periodontal diseases by blocking tissue-destructive enzymes J Am Dent Assoc 125 2 1994 163 169
42. W. Bode, E. Meyer Jr., and J.C. Powers Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors Biochemistry 28 5 1989 1951 1963 (Pubitemid 19084420)
43. Q.L. Ying, A.R. Rinehart, S.R. Simon, and J.C. Cheronis Inhibition of human leucocyte elastase by ursolic acid. Evidence for a binding site for pentacyclic triterpenes Biochem J 277 Pt 2 1991 521 526
44. K.M. Chang, M.E. Ryan, L.M. Golub, N.S. Ramamurthy, and T.F. McNamara Local and systemic factors in periodontal disease increase matrix-degrading enzyme activities in rat gingiva: effect of minocycline therapy Res Commun Mol Pathol Pharmacol 91 3 1996 303 318 (Pubitemid 26149051)
45. J. Steinberg, J. Halter, H. Schiller, L. Gatto, D. Carney, and H.M. Lee Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model Shock 24 4 2005 348 356 (Pubitemid 41416521)
46. J.M. Halter, L.A. Pavone, J.M. Steinberg, L.A. Gatto, J. DiRocco, and S. Landas Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture Crit Care Med 30 12 2002 2675 2683
47. J. Steinberg, J. Halter, H.J. Schiller, M. Dasilva, S. Landas, and L.A. Gatto Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats J Surg Res 111 2 2003 185 195 (Pubitemid 36808908)